E
Elliott M. Antman
Researcher at Brigham and Women's Hospital
Publications - 738
Citations - 187175
Elliott M. Antman is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 161, co-authored 716 publications receiving 179462 citations. Previous affiliations of Elliott M. Antman include Duke University & Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
Effect of the Novel Thienopyridine Prasugrel Compared With Clopidogrel on Spontaneous and Procedural Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 An Application of the Classification System From the Universal Definition of Myocardial Infarction
David A. Morrow,Stephen D. Wiviott,Harvey D. White,Jose C. Nicolau,Ezio Bramucci,Sabina A. Murphy,Marc P. Bonaca,Christian T. Ruff,Benjamin M. Scirica,Carolyn H. McCabe,Elliott M. Antman,Eugene Braunwald +11 more
TL;DR: In this paper, the authors compared prasugrel with clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention, and found that the latter significantly reduced the risk of myocardial infarction.
Journal ArticleDOI
Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction
C M Gibson,K. Ryan,Sabina A. Murphy,Rebecca Mesley,Susan J. Marble,Robert P. Giugliano,Christopher P. Cannon,Elliott M. Antman,Eugene Braunwald +8 more
TL;DR: Acute MI slows flow globally, and slower global flow is associated with adverse outcomes, especially in patients who died and patients who survived.
Journal ArticleDOI
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial
Jessica L. Mega,Joseph R. Walker,Christian T. Ruff,Alexander G. Vandell,Francesco Nordio,Naveen Deenadayalu,Sabina A. Murphy,James Lee,Michele Mercuri,Robert P. Giugliano,Elliott M. Antman,Eugene Braunwald,Marc S. Sabatine +12 more
TL;DR: After 90 days, the reduction in bleeding risk with edoxaban versus warfarin was similarly beneficial across genotypes, and treatment with Edoxaban reduced bleeding more so in sensitive and highly sensitive responders than in normal responders.
Journal ArticleDOI
Cost-Effectiveness of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention Results From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction TRITON-TIMI 38
Elizabeth M. Mahoney,Kaijun Wang,Suzanne V. Arnold,Irina Proskorovsky,Stephen D. Wiviott,Elliott M. Antman,Eugene Braunwald,David J. Cohen +7 more
TL;DR: Among acute coronary syndrome patients with planned percutaneous coronary intervention, treatment with prasugrel versus clopidogrel for up to 15 months is an economically attractive treatment strategy.
Journal ArticleDOI
ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: Executive summary - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writi
Jeffrey L. Anderson,Cynthia D. Adams,Elliott M. Antman,Charles R. Bridges,Robert M. Califf,Donald E. Casey,William E. Chavey,Francis M. Fesmire,Judith S. Hochman,Thomas N. Levin,A. Michael Lincoff,Eric D. Peterson,Pierre Theroux,Nanette K. Wenger,R. Scott Wright,Sidney C. Smith,Alice K. Jacobs,Jonathan L. Halperin,Sharon A. Hunt,Harlan M. Krumholz,Frederick G. Kushner,Bruce W. Lytle,Rick A. Nishimura,Joseph P. Ornato,Richard L. Page,Barbara Riegel +25 more